Radioimmunoassays Market by Type, Product Type, Application, End-User

List of Tables

The Radioimmunoassays Market is projected to reach USD 612.00 million by 2030 from USD 430.39 million in 2022, at a CAGR of 4.49% during the forecast period.

Global Radioimmunoassays Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 430.39 million
Estimated Year Value [2023]	USD 448.94 million
Forecast Year Value [2030]	USD 612.00 million
CAGR (%)	4.49%

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Radioimmunoassays Market.

Based on Type, market is studied across Coated-Tube RIA and Double-Antibody RIA. The Double-Antibody RIA is projected to witness significant market share during forecast period.

Based on Product Type, market is studied across Analyzers and Reagents & Kits. The Reagents & Kits is projected to witness significant market share during forecast period.

Based on Application, market is studied across Clinical Diagnostics and Research. The Research is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Academic & Research Institutes, Clinical Diagnostic Laboratories, Hospitals, and Pharmaceuticals & CROs. The Academic & Research Institutes is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Radioimmunoassays Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Radioimmunoassays Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Radioimmunoassays Market, highlighting leading vendors and their innovative profiles. These include Abbexa Limited, Abcam Plc, ALPCO, Antigenix America, Inc., Berthold Technologies GmbH & Co.KG, Biosynth Ltd, BioVendor - Laboratorni medicina a.s., Creative Biomart, Inc., Danaher Corporation, Demeditec Diagnostics GmbH, Diasorine S.P.A., DRG International, Inc. by BioCheck Inc., Drive DeVilbiss International, EUROIMMUN Medizinische Labordiagnostika AG, Hidex Oy., IBL International GmbH, Immuno-Biological Laboratories, Inc., Institute of Isotopes Co. Ltd., LKB Instruments, LubioScience GmbH, Marin Biologic Laboratories, Inc., Merck & Co, Inc, Montreal Biotech Inc., MP Biomedicals, LLC, NovoLytix GmbH, Padyab Teb Co., and PerkinElmer Inc..

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Radioimmunoassays Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Radioimmunoassays Market?

3. What is the competitive strategic window for identifying opportunities in the Radioimmunoassays Market?

4. What are the latest technology trends and regulatory frameworks in the Radioimmunoassays Market?

5. What is the market share of the leading vendors in the Radioimmunoassays Market?

6. Which modes and strategic moves are suitable for entering the Radioimmunoassays Market?

Product Code: MRR-C002B1C99654

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Radioimmunoassays Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing prevalence of chronic and infectious disease
  - 5.1.1.2. Increasing number of imaging centers across the globe
  - 5.1.1.3. Rapid shift towards early diagnosis and surge in healthcare expenditure
- 5.1.2. Restraints
  - 5.1.2.1. Short shelf life and associated hazards concern with radioactive materials
- 5.1.3. Opportunities
  - 5.1.3.1. Surge in government funding for life science research activity
  - 5.1.3.2. Integration of advanced technology for disease diagnostics
- 5.1.4. Challenges
  - 5.1.4.1. Presence of alternative advanced immunoassays and the dearth of skilled professionals
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Radioimmunoassays Market, by Type

6.1. Introduction
6.2. Coated-Tube RIA
6.3. Double-Antibody RIA

7. Radioimmunoassays Market, by Product Type

7.1. Introduction
7.2. Analyzers
7.3. Reagents & Kits

8. Radioimmunoassays Market, by Application

8.1. Introduction
8.2. Clinical Diagnostics
8.3. Research

9. Radioimmunoassays Market, by End-User

9.1. Introduction
9.2. Academic & Research Institutes
9.3. Clinical Diagnostic Laboratories
9.4. Hospitals
9.5. Pharmaceuticals & CROs

10. Americas Radioimmunoassays Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Radioimmunoassays Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Radioimmunoassays Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. Abbexa Limited
- 14.1.2. Abcam Plc
- 14.1.3. ALPCO
- 14.1.4. Antigenix America, Inc.
- 14.1.5. Berthold Technologies GmbH & Co.KG
- 14.1.6. Biosynth Ltd
- 14.1.7. BioVendor - Laboratorni medicina a.s.
- 14.1.8. Creative Biomart, Inc.
- 14.1.9. Danaher Corporation
- 14.1.10. Demeditec Diagnostics GmbH
- 14.1.11. Diasorine S.P.A.
- 14.1.12. DRG International, Inc. by BioCheck Inc.
- 14.1.13. Drive DeVilbiss International
- 14.1.14. EUROIMMUN Medizinische Labordiagnostika AG
- 14.1.15. Hidex Oy.
- 14.1.16. IBL International GmbH
- 14.1.17. Immuno-Biological Laboratories, Inc.
- 14.1.18. Institute of Isotopes Co. Ltd.
- 14.1.19. LKB Instruments
- 14.1.20. LubioScience GmbH
- 14.1.21. Marin Biologic Laboratories, Inc.
- 14.1.22. Merck & Co, Inc
- 14.1.23. Montreal Biotech Inc.
- 14.1.24. MP Biomedicals, LLC
- 14.1.25. NovoLytix GmbH
- 14.1.26. Padyab Teb Co.
- 14.1.27. PerkinElmer Inc.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing